The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

There have been revisions to the prescribing information for Xolair. The drug is used to treat moderate to severe asthma in individuals 12 years old and older. There is a risk of anaphylaxis with use of Xolair. Anaphylaxis is a severe allergic reaction, with symmptoms such as wheezing, trouble breathing, hives, dizziness and throat tightness. New information about this risk has been added to the Xolair prescribing information, which now includes a new Boxed Warning, updated Warnings, Precautions and Adverse Reactions- – Postmarketing Spontaneous Reports. Also, each dosage of Xolair is to be accompanied by a New Medication Guide regarding the anaphylaxix risk.

For more information on this subject, please refer to our section on Drugs, Medical Devices, and Implants.

Comments are closed.

Of Interest